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PreviewsIn summary, the development of
MitoSOD by Kelso et al. (2012) is a
notable advancement in the field be-
cause it introduces a new and previously
neglected chapter in the development
of SOD mimetics. This is timely since it
is quite clear that controlled production
of superoxide both in the cytosol, by
NADPH oxidases, and in the mitochon-
drion play an important role in the normal
physiology and pathology of disease.
We look forward to the application of
this exciting new technology to unravel
the redox signaling networks controlling
key events such as cell differentiation
and apoptosis.
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Aptamers are RNA molecules that bind small molecules. They were originally isolated from random libraries
and then found in bacteria. In this issue ofChemistry & Biology, Vu et al. demonstrate that amotif for an aden-
osine aptamer occurs in human and bacterial genomes and binds AMP and ATP in vitro.RNA possesses both structural and func-
tional diversity. Structural diversity arises
because RNA is single stranded and can
fold back on itself, attainingmyriad imper-
fections such as bulges and loops. These
are key to structural diversity, as they form
small clefts or interact with other regions
of the RNA to make large clefts. Such
clefts can bind small molecules, giving
rise to specific molecular recognition
and ribozyme catalysis.
In theearly 1990s, groundbreakingwork
led to the identification of RNA sequences
that bind small molecules tightly and
specifically, so-called ‘‘aptamers,’’ and
established RNA enzymes with novel
functions, so-called ‘‘ribozymes’’. The
generation of these sequences relied
on a process referred to as ‘‘SELEX’’ orin vitro selection, in which random RNA
libraries, generated by transcription from
randomized DNA templates, were chal-
lenged to bind small molecules.
One of the early in vitro selection
studies, conducted by Sassanfar and
Szostak (1993), focused on the binding
of an RNA library to ATP. After eight
rounds of selection, aptamers were iso-
lated that had a fairly simple motif of an
1131 asymmetric internal loop flanked
by stems, for a total aptamer size of just
35–40 nt (Figure 1, bottom). Secondary
structure probing and structure determi-
nation revealed that this aptamer is
comprised of a simple fold-back structure
with a cleft (Dieckmann et al., 1996; Jiang
et al., 1996; Sassanfar and Szostak,
1993). This aptamer bound ATP, AMP,and adenosine with low mM Kds and
discriminated against CTP, GTP, and
UTP, as well as most ribose sugar modifi-
cations. One key question that emerged
was whether the ATP aptamer is relevant
to biology.
Over the past decade, work from
several labs has revealed that RNA
aptamers occur in nature as ‘‘ribos-
witches,’’ where they comprise an ‘‘ap-
tamer domain’’ that couples to an
‘‘expression platform’’ which effects
changes in gene expression upon ligand
binding (Grundy and Henkin, 1993; Miro-
nov et al., 2002; Winkler et al., 2002).
Riboswitches can be either ‘‘indirect,’’
binding a metabolite-sensing protein, or
‘‘direct,’’ binding a larger RNA or ametab-
olite themselves (Nilsen, 2007). Among
Figure 1. All Roads Lead to the Same Adenosine-Binding Motif
Shown are three approaches to identify adenosine aptamers. Random SELEX, genomic SELEX, and
structure-based bioinformatics all lead to the same simple ATP-binding motif, which is comprised of an
1131 asymmetric internal loop (blue and red) flanked by stems (black), with ATP bound (yellow) in the
internal loop. The approaches are illustrated with the actual secondary structures, the search descriptor
used in structure-based bioinformatics, and the 3D structure of the ATP aptamer (center) (pdb id 1RAW).
Note that the 11 nt recognition loop can occur in the 30-strand as well, as it does in bacteria; thus, no loops
are shown for the motif for structure-based bioinformatics or Random SELEX. An arbitrary base pair is
highlighted in green in all structures for orientation. Genomic SELEX also identified an aptamer near
ERV1 (not depicted).
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Previewsthe riboswitches identified to date is an
adenine riboswitch, in which the adenine
turns on a purine efflux pump (Mandal
and Breaker, 2004). This RNA has a
much more complex fold than the ATP
aptamer, having 80 nts or roughly twice
as many nucleotides.
Isolation of aptamers from random
libraries and their subsequent discovery
and function in biology represents an
astonishing one-two punch for RNA
structure and function. This led to specu-
lation about the existence of a so-called
‘‘RNA world’’ and the function of RNA
molecules during that era. In addition,
identification of aptamers led to the
hypothesis that they might exist in human
biology. To date, nearly all known ribos-
witches occur in bacteria (the one excep-
tion is in plants), where they regulate
an astonishing number of genes—at
least 4% of all genes in Bacillus subtilis
(Irnov et al., 2006). In this issue of
Chemistry & Biology, Vu et al. (2012) iden-
tify several putative adenosine aptamers
in human and bacterial genomes, using
both computational and experimental
approaches.The authors first describe their in silico
structure-based searches in which they
use bioinformatics to identify sequences
that conform to theSassanfar andSzostak
motif. The researchers create a computa-
tional ‘‘descriptor’’ of the motif and then
use a secondary structure search algo-
rithm to find sequences in genomic data
capable of folding into the desired struc-
ture. As the algorithmmakes its selections
on the ability to base pair and not the
actual energetics of the fold, the authors
subsequently narrow down the pool of
sequences using free energy folding algo-
rithms. The top aptamer candidate
sequences are then transcribed and
tested for ATP binding in vitro.
The authors then turn to in vitro experi-
ments in the form of genomic SELEX to
search for ATP binders in the human
genome. In this portion of the study, they
perform a genome-based selection of
RNA aptamers by using an 150 nt
human genomic library instead of tran-
scribing from a chemically synthesized
template. One interesting aspect of this
experiment is its potential to identify
RNA with folds differently from the previ-Chemistry & Biology 19, October 26, 2012 ªously identified 1131 loop. The identified
aptamers are then tested for strength of
ATP binding.
Excitingly, sequences that bind ATP
were found in the human genome using
both approaches. Structure-based bio-
informatics identified an aptamer in the
RAB3C intron (Figure 1, right), while
genomic selection identified one in the
FGD3 intron (Figure 1, left) and another
near ERV1. Curiously, the latter two
aptamers still conformed to the original
motif of Sassanfar and Szostak. Vu et al.
(2012) demonstrate that these sequences
bind ATP and AMP in vitro, discriminate
against GTP and dATP, and fold correctly.
Moreover, they show that thesemotifs are
conserved in several primates and also
occur in bacteria.
The fact that aptamers isolated by
genomic SELEX and structure-based bio-
informatics led to the same 1131 motif
first identified in the Szostak lab suggests
that this motif represents a robust and
perhaps unique solution to binding of
adenosine, at least for a smaller motif.
Although this motif is simpler than the
adenine riboswitch, it still has sizable
information content at35 bits (Carothers
et al., 2004), predicting that the chance
the aptamer should appear in the human
genome by luck is about 1 in 10. That
the authors identified three putative ap-
tamers in the human genome and these
bound during genomic SELEX, beats the
odds by 1 in 103. These statistics
combined with the conservation of these
sequences in primates suggests that
there may be selective pressures to main-
tain these sequences and thus that
perhaps they function to sense ATP in
the cell.
As the authors state, future experi-
ments will be needed to test whether
these aptamers bind ATP and regulate
gene function in vivo. Curiously, each of
the two genes that contain the aptamer
has a function related to guanine—
RAB3C codes for a GTPase and FGD3
for a guanyl nucleotide exchange factor;
although RAB3C was shown to not bind
GTP, perhaps guanine function is linked
to ATP levels in some way. Discovery of
a biological function for the direct recog-
nition of adenosine, or any other small
molecule for that matter, by RNA would
stand to revolutionize our understanding
of gene regulation in humans and further
cement RNA’s central role in biology.2012 Elsevier Ltd All rights reserved 1219
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Antibiotic-producing microoganisms are a reservoir of drug resistance genes. Studies of the ‘‘antibiotic
resistome’’ can inform antimicrobial drug discovery and explain the emergence of multidrug resistant
pathogens. In this issue of Chemistry & Biology, Westman and colleagues take an alternative look at the
resistome and identify genes that could be used to detoxify the anticancer compound, doxorubicin.This year marks the sixtieth anniversary of
the awarding of the Nobel Prize in medi-
cine or physiology to Selman Waksman
for his discovery of streptomycin, the
first effective treatment for tuberculosis.
The utilization of streptomycin in clinical
settings was a landmark in medicine that
saved millions of lives. Remarkably, the
concepts that Waksman developed and
the strategies that he used to discover
streptomycin (Schatz and Bugle, 1944)
have proven to bemore important inmedi-
cine than the drug itself. Specifically,
Waksman coined the term antibiotic to
describemolecules produced bymicroor-
ganisms that kill or compromise the
growth of other microorganisms. By this
definition, antibiotics represent a large
subset of molecules known as either
natural products or secondary metabo-
lites. He predicted and demonstrated
that antimicrobial drug discovery could
be enabled via systematic isolation of
microorganisms from soil, followed by
assays of their ability to produce antibi-
otics that were toxic to human pathogens.
Waksman’s use of this strategy to dis-
cover two blockbuster antibacterial drugs(streptomycin and neomycin) inspired
countless scientists in industry and
academe whose work has resulted in the
identification of more than 12,000 antibi-
otics (Demain, 1999). Although most of
these molecules are either too toxic for
clinical use or have pharmacological liabil-
ities, a fraction of them are useful asmedi-
cines for the treatment of bacterial and
fungal infections. Although Waksman did
not initially envision it, a subset of antibi-
otics is also used as anticancer drugs
and as immunosuppressants. Suffice to
say, exploitation of antibiotics has revolu-
tionized medicine in many ways.
The growing number of infections and
mortalities caused by multi-drug resistant
bacteria and fungi has renewed interests
in antibiotics from two different perspec-
tives. In one, the rich history of antibiotics
in medicine and the vastness of untapped
biodiversity are used to justify searches
for new molecules from microorganisms
that may be tomorrow’s drugs or drug
leads (Lewis, 2012). Today, the Waksman
drug discovery strategy is being comple-
mented by ‘‘omics’’ approaches wherein
genomes or metagenomes are bioinfor-matically mined in search of genetic
potential for the biosynthesis of novel
antibiotics (Iqbal et al., 2012; Knerr and
van der Donk, 2012). From the other
perspective, antibiotic resistance is of
interest because many antimicrobial
drugs are antibiotics or synthetic deriva-
tives thereof. It is anticipated that knowl-
edge of the molecular mechanisms by
which microorganisms resist antibiotics
could enable the rational design of strate-
gies that will restore the potency or
extend the life span of antimicrobial drugs
(Okandeji et al., 2011). Further, identifica-
tion of antibiotic resistance genes that
render microorganisms insusceptible to
promising drug candidates and subse-
quent determination of the genes’ distri-
bution in bacterial populations could be
used to critical advantage in drug devel-
opment programs (Vecchione and Sello,
2009).
In principle, if one wants to discover
antimicrobial drug resistance genes, then
one could analyze antibiotic-producing
bacteria that must harbor antibiotic resis-
tance genes to avoid suicide. On this
basis, it has been proposed that the
